Close Menu

Drugs like Genentech's Herceptin show what biotech can do when it comes to innovating blockbuster treatments, says Robert Langreth on the Forbes Treatments blog. Indeed by 2014, analysts predict that the top five bestselling drugs will have come from biotech. The problem is, no one wants to pay for the next generation of treatments, like those derived from stem cells, that could be hitting the market around 2020, Langreth says.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Reuters reports that Germany is seeking to sequence 5 percent of patient samples that test positive for SARS-CoV-2.

23andMe and Medscape say primary care physicians are increasingly more comfortable with discussing direct-to-consumer genetic testing results.

The publisher of the Science family of journals will allow some authors to place peer-reviewed versions of their papers into publicly accessible repositories.

In Science this week: analysis of genome-wide association studies of chronic kidney disease, and more.